In addition, the genetic effects of COX2 and PLA2 as well the therapeutic effects of n-3 PUFAs on specific symptoms, for example, depressive symptoms in CVD or somatic symptoms, such as HRV, chest tightness, dyspnea, somatic pain symptoms in depression, are also very important to support our hypothesis. The gene discussed is PLA2G6; the disease is depressive disorder.